Business Wire
30 Sept 2026, 11:45 UTC · 1h ago
Verdict
Headline takes no side. We score IMNM +0.80 across one claim — strongly bullish.
+0.80strongly bullish
More positive than 89% of ticker scores this week
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
The FDA has cleared the Investigational New Drug (IND) application for Immunome's IM-1340 antibody-drug conjugate for advanced solid tumors.
Newannounced today in press release
So whatClearance allows the company to initiate Phase 1 clinical trials within the coming months.
More positive than 94% of claims this week
Which stocks this story touches
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 89% of ticker scores this week
FDA clearance of its IND application for IM-1340 is a significant regulatory milestone.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Proactive Investors
5h ago
—
IMNM hasn't traded since this ran. Last close $21.89 (Sep 29); the reaction starts at the next open.
IMNM chart →
